Akero Therapeutics Inc (AKRO)

Akero Therapeutics Stock Analysis & Ratings

AKRO Stock Chart & Stats

Day’s Range$8.78 - $9.32
52-Week Range$8.50 - $30.53
Previous Close$8.98
Average Volume (3M)238.91K
Market Cap$314.16M
P/E Ratio-2.8
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-3.20



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Akero Therapeutics’s price range in the past 12 months?
Akero Therapeutics lowest stock price was $8.50 and its highest was $30.53 in the past 12 months.
    What is Akero Therapeutics’s market cap?
    Akero Therapeutics’s market cap is $314.16M.
      What is Akero Therapeutics’s price target?
      The average price target for Akero Therapeutics is $62.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $62.00 ,the lowest forecast is $62.00. The average price target represents 591.19% Increase from the current price of $8.97.
        What do analysts say about Akero Therapeutics?
        Akero Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Akero Therapeutics’s upcoming earnings report date?
          Akero Therapeutics’s upcoming earnings report date is Aug 16, 2022 which is in 85 days.
            How were Akero Therapeutics’s earnings last quarter?
            Akero Therapeutics released its earnings results on May 06, 2022. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.798 by $0.058.
              Is Akero Therapeutics overvalued?
              According to Wall Street analysts Akero Therapeutics’s price is currently Undervalued.
                Does Akero Therapeutics pay dividends?
                Akero Therapeutics does not currently pay dividends.
                What is Akero Therapeutics’s EPS estimate?
                Akero Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Akero Therapeutics have?
                Akero Therapeutics has 35,020,000 shares outstanding.
                  What happened to Akero Therapeutics’s price movement after its last earnings report?
                  Akero Therapeutics reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.798. Following the earnings report the stock price went down -1.5%.
                    Which hedge fund is a major shareholder of Akero Therapeutics?
                    Among the largest hedge funds holding Akero Therapeutics’s share is Versant Venture Management, LLC. It holds Akero Therapeutics’s shares valued at 9M.


                      Akero Therapeutics Stock Analysis

                      The Akero Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Akero Therapeutics Inc

                      Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

                      Similar Stocks
                      Price & Change
                      TCR2 Therapeutics
                      Harpoon Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis